융합 생검 시장 : 루트 유형별, 용도별, 제품별, 최종 사용자별, 지역별 - 예측(-2029년)

The global fusion biopsy market is valued at an estimated 0.65 billion in 2024 and is projected to reach USD 0.91 billion by 2029, at a CAGR of 7.1% during the forecast period. The old population is causing a rise in age-related health conditions, such as prostate cancer, which predominantly affects older men. As these elderly individuals grows globally, the incidence of prostate cancer is also expected to increase leading to increased demand for advanced diagnostic technologies such as fusion biopsy. The increase in demand is especially seen in areas with older populations, like Europe and North America. These regions have healthcare systems that are better able to use advanced technologies like fusion biopsy.

"The equipment segment is projected to witness the highest growth rate in the fusion biopsy market, by product, during the forecast period."

Based on product, the fusion biopsy market is segmented into equipment and consumables. The growth of equipment segment is owing to their ability to combine high-resolution imaging with real-time ultrasound for precise targeting of suspicious lesions. The demand for these equipment is fueled by the increasing prevalence of prostate cancer, the adoption of minimally invasive procedures, and ongoing technological advancements, such as AI integration for better lesion detection, further accelerates the growth of this segment.

"In 2023, the prostate cancer segment accounted for the largest share of the fusion biopsy market, by application."

Prostate cancer and other applications make up the application-based segments of the fusion biopsy market. Market share for fusion biopsy was highest in the prostate cancer in 2023. The high incidence of prostate cancer worldwide and the efficiency of fusion biopsy in identifying these clinically relevant malignancies are the primary causes of this high percentage. Improvements in imaging technology and growing awareness of early detection further support this the lead, guaranteeing its sustained market leadership in fusion biopsy.

"The Asia Pacific region is projected to witness highest growth rate in the fusion biopsy market during the forecast period"

The global fusion biopsy market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the fusion biopsy market is expected to grow at the fastest rate in the Asia Pacific region. The rising healthcare investments, a growing prevalence of cancers like prostate cancer, and a large aging population vulnerable to cancer contribute to the significant market growth in the Asia Pacific region during the projected period.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 35%, Europe - 31%, Asia Pacific - 22%, Latin America - 9%, Middle East & Africa - 2%, and the GCC Countries - 1%

Lists of Companies Profiled in the Report:

Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)

Research Coverage:

In this report, the fusion biopsy market has been categorized based on product (equipment and consumables), end user (hospitals and other end users), route type (transsrectal, transperineal, and other route types), application (prostate cancer and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).

Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the fusion biopsy market's expansion is included in detail in this study. An exhaustive study of the key players in the fusion biopsy market has been done to provide insights into their business profile, products offered, noteworthy strategies, collaborations, and other recent activities pertaining to the market.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall fusion biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.

The report provides insights on the following pointers:

• Analysis of key drivers: (Increasing prevalence of prostate cancer and growing gearitric population, availability of reimbursements and investments by public and private sector, and rising prevalence of minimally invasive surgery), restraints (High cost of fusio biopsy system and alternative methods for fusion biopsy), opportunities (Rise in prevalence of prostate cancer in emerging economies and technological advancements in fusion biopsy devices), and challenges (Paucity of skilled professionals and limited reimbursement in few countries) influencing the growth of the in fusion biopsy market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research development activities, and new product launches in the fusion biopsy market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the fusion biopsy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the fusion biopsy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), and KOELIS (France) are among others, in the fusion biopsy market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 GROWTH RATE ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 FUSION BIOPSY MARKET OVERVIEW
• 4.2 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION AND COUNTRY (2023)
• 4.3 FUSION BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 FUSION BIOPSY MARKET: REGIONAL MIX (2024-2029)
• 4.5 FUSION BIOPSY MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of prostate cancer and growing geriatric population
    • 5.2.1.2 Availability of reimbursements and investments by public and private sectors
    • 5.2.1.3 Rising prevalence of minimally invasive surgery
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of fusion biopsy systems
    • 5.2.2.2 Alternative methods for fusion biopsy
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rise in prevalence of prostate cancer in emerging economies
    • 5.2.3.2 Technological advancements in fusion biopsy devices
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Paucity of skilled professionals
    • 5.2.4.2 Limited reimbursement in few countries
• 5.3 PRICING ANALYSIS
  • 5.3.1 PRICING ANALYSIS, BY REGION
  • 5.3.2 PRICING ANALYSIS, BY PRODUCT
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 NORTH AMERICA
    • 5.9.1.1 US
    • 5.9.1.2 Canada
  • 5.9.2 EUROPE
  • 5.9.3 ASIA PACIFIC
    • 5.9.3.1 Japan
    • 5.9.3.2 China
    • 5.9.3.3 India
  • 5.9.4 LATIN AMERICA
    • 5.9.4.1 BRAZIL
    • 5.9.4.2 MEXICO
  • 5.9.5 MIDDLE EAST
  • 5.9.6 AFRICA
  • 5.9.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 TRADE ANALYSIS
  • 5.10.1 TRADE ANALYSIS FOR FUSION BIOPSY MARKET
• 5.11 PATENT ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS IN 2024-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.14 TECHNOLOGY ANALYSIS
  • 5.14.1 KEY TECHNOLOGIES
    • 5.14.1.1 MRI-ultrasound fusion imaging
  • 5.14.2 COMPLEMENTARY TECHNOLOGIES
    • 5.14.2.1 Liquid biopsy
      • 5.14.2.1.1 Digital droplet PCR
      • 5.14.2.1.2 Tagged-amplicon deep sequencing
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET

6 FUSION BIOPSY MARKET, BY ROUTE TYPE

• 6.1 INTRODUCTION
• 6.2 TRANSRECTAL
  • 6.2.1 HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO HINDER MARKET GROWTH
• 6.3 TRANSPERINEAL
  • 6.3.1 IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH
• 6.4 OTHER ROUTE TYPES

7 FUSION BIOPSY MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 PROSTATE CANCER
  • 7.2.1 PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH
• 7.3 OTHER APPLICATIONS

8 FUSION BIOPSY MARKET, BY PRODUCT

• 8.1 INTRODUCTION
• 8.2 EQUIPMENT
  • 8.2.1 SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH
• 8.3 CONSUMABLES
  • 8.3.1 INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH

9 FUSION BIOPSY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO PROMOTE MARKET GROWTH
• 9.3 OTHER END USERS

10 FUSION BIOPSY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Funding for cancer research and availability of technologically advanced products to propel market growth
  • 10.2.3 CANADA
    • 10.2.3.1 Surging need for advanced diagnostic solutions to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Rising healthcare expenditure and increasing incidence of cancer to bolster market growth
  • 10.3.3 UK
    • 10.3.3.1 Enhanced clinical infrastructure to accelerate fusion biopsy adoption
  • 10.3.4 FRANCE
    • 10.3.4.1 Effective reimbursement policies and government support for surgical product manufacturers to augment market
  • 10.3.5 ITALY
    • 10.3.5.1 Rising healthcare demands of geriatric population to support market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Improved healthcare infrastructure and rising geriatric demographics to boost market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing disposable income of middle-class population and rising diagnostic procedures to boost market
  • 10.4.3 JAPAN
    • 10.4.3.1 Robust healthcare system and surging need for precise early cancer detection to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Large patient population and increasing healthcare investments to drive market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH
  • 10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN FUSION BIOPSY MARKET
• 11.3 REVENUE SHARE ANALYSIS, 2021-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Route type footprint
    • 11.5.5.4 Product footprint
    • 11.5.5.5 Application footprint
    • 11.5.5.6 End user footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 STARTING BLOCKS
  • 11.6.3 RESPONSIVE COMPANIES
  • 11.6.4 DYNAMIC COMPANIES
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 KONINKLIJKE PHILIPS N.V.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Key strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 GE HEALTHCARE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Right to win
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses & competitive threats
  • 12.1.3 KOELIS
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 FUJIFILM HOLDINGS CORPORATION
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches & approvals
  • 12.1.5 CANON INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
  • 12.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 ESAOTE SPA
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 EIGEN HEALTH
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 FOCAL HEALTHCARE
  • 12.2.2 MTT GMBH
  • 12.2.3 MEDCOM
  • 12.2.4 UC-CARE MEDICAL SYSTEMS
  • 12.2.5 BIOBOT SURGICAL

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS